Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Teva
Colorcon
Covington
Harvard Business School
Healthtrust
Baxter
Mallinckrodt
Fuji
US Department of Justice

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,160,559

« Back to Dashboard

Summary for Patent: 7,160,559
Title:Controlled release galantamine composition
Abstract:The present invention is concerned with controlled release compositions for oral administration comprising galantamine; and with processes of preparing such controlled release compositions.
Inventor(s): McGee; John Paul (Antwerp, BE), Gilis; Paul Marie Victor (Beerse, BE), De Weer; Marc Maurice Germain (Vosselaar, BE), de Conde; Valentin Florent Victor (Lommel, BE), de Bruijn; Herman Johannes Catherina (Meer, BE), Van Dycke; Frederic Anne Rodolf (Antwerp, BE)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:09/868,991
Patent Claim Types:
see list of patent claims
Formulation; Compound; Device; Process; Use; Dosage form;

Drugs Protected by US Patent 7,160,559

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-001 Apr 1, 2005 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-002 Apr 1, 2005 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-003 Apr 1, 2005 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,160,559

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
98204447Dec 24, 1998
PCT Information
PCT FiledDecember 20, 1999PCT Application Number:PCT/EP99/10257
PCT Publication Date:July 06, 2000PCT Publication Number: WO00/38686

International Patents Family Members for US Patent 7,160,559

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2358062 ➤ Sign Up
China 1331596 ➤ Sign Up
China 100370990 ➤ Sign Up
Czech Republic 20012182 ➤ Sign Up
Czech Republic 301658 ➤ Sign Up
Germany 69912311 ➤ Sign Up
Denmark 1140105 ➤ Sign Up
Eurasian Patent Organization 200100713 ➤ Sign Up
Eurasian Patent Organization 004936 ➤ Sign Up
Estonia 200100319 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Dow
Farmers Insurance
Daiichi Sankyo
Accenture
Deloitte
AstraZeneca
Boehringer Ingelheim
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot